Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihyperten... ( HAYWARD Calif. Nov. 1 /- Arete Th...)

Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent

Date:11/1/2007

HAYWARD, Calif., Nov. 1 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a phase 1 clinical trial for its lead compound, AR9281, for the treatment of hypertension. AR9281 is a "first-in-class," orally-active inhibitor of soluble epoxide hydrolase (s-EH), a novel target for the treatment of hypertension. The trial will enroll up to 32 healthy adult volunteers and will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics for single ascending doses of AR9281.

"AR9281 inhibits s-EH, an enzyme that plays a key role in the cytochrome P450 pathway of arachidonic acid metabolism, and offers a unique mechanism of action as an antihypertensive agent," said Dinesh V. Patel, Ph.D., president and chief executive officer of Arete Therapeutics Inc. "We believe this first-in-class compound has great potential to be a unique 'antihypertensive-plus' drug that not only lowers blood pressure but also offers end organ protection of the heart and kidney, and protection against vascular inflammation."

"The preclinical safety and efficacy profile of AR9281 is very encouraging and provided a solid basis for the initiation of the clinical development phase of this new compound class," commented Randall Whitcomb, M.D., chief medical officer of Arete Therapeutics Inc. "We look forward to reporting results from the initial phase 1 clinical trial in 2008."

Arete Therapeutics' phase 1 single ascending dose, placebo-controlled clinical trial in healthy volunteers will obtain initial safety and tolerance information as well as detailed blood pressure measurements. Levels of s-EH specific biomarkers will be analyzed together with typical inflammatory markers as part of the pharmacodynamic assessment. Following successful completion of the single dose study, Arete plans to initiate a multiple dose phase 1 study, a food effect study, and studies in special populations.

About AR9281

AR9281 is a novel small molecule inhibi
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3
Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. Bird Flu: Orissa Initiates Protective Measures
4. Biota Initiates Drug Testing War against Common Cold
5. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
6. Government Initiates A Program To Curb HIV
7. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
8. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
9. Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
10. FDA approves Phase 0 trial which tests experimental drugs on humans
11. SARS-Free Taiwan to Mark End Phase of Global Fight

Post Your Comments:

(Date:12/1/2009)...ewswire-USNewswire/ -- The following is being rele...ent: ,, Chairman Kerry, Ranking Member Lugar, a... be nominated by President Obama to serve as Admin...onal Development, and I appreciate his confidence ...e Clinton has expressed the conviction that, along...

(Date:12/1/2009)...hority Encourages Older Persons and Healthcare Wor... Based Upon Authority Data ,, HARRISBURG, Pa.... of all vaccine preventable deaths occur in those ..., according to highlighted studies in the Pennsylv...ient Safety Advisory . ,, According to the Cent...

(Date:12/1/2009)...rforming surgical operations without leaving scars...ty. This is demonstrated by the recent surgical ad...nal Endoscopy Surgery), an innovative surgical app... natural orifices. The results are all advantageou... stay and faster recovery. Currently, this type of...

(Date:12/1/2009)...ness declines with age are more likely to engage i...heir misguided negative view of the aging process ... encourage them to make the most of the present in...ngs 1 by Dr. John Garry and Dr. Maria Lohan from ...published online in Springer,s Journal of Happine...

(Date:12/1/2009)...iversit de Montral researcher, funded by the Inter...d Violence Against Women, has launched a new study... started our research seeking men in their twentie...find any," says Simon Louis Lajeunesse, a postdoct... Work. , "The objective of my work is to observ...

[0] Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 [1] Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory [0] Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus [0] Binge drinking youths find getting old a drag [0] Are the effects of pornography negligible?

...N, Mass., Aug. 5 Indevus,Pharmaceuticals, Inc. (N...sults of operations for the third quarter ended Ju...ll and webcast today beginning at 9:00 am,eastern ...quarter ended June 30,2008. This compares to reven...

... Allsup explains the pros, cons ...owing a long-term disabling event, especially duri...ce benefits , Belleville,...use of a disability, according to http://allsup.c...

... Cenegenics® Medical Institu...nnounced the opening of Cenegenics Indiana. The c...hing over 2008-2009. The new Cenegenics Indiana wi...ptured global media attention, such as 60 Minutes,...

... QHR client hospital Gritman Med...st, Pullman Regional Hospital, were recently ranke...re and Medicaid Services (CMS) in "overall pa...n physician recruitment and share medical equipmen...

... The rapid growth in popularity ...ny skeptics wrong. A recent poll shows that the b...umers, privacy concerns. From dating, through gen... Carlsbad, Calif. (PRWEB) August 5, 2...

...BEACH, Calif., Aug. 5 Today the United States,Pat...ronmentally "Green",low cost process that eliminat...g oxidants. The patent includes methods for abatin... processes,there is a significant increase in effi...

Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results Ten Questions to Ask When Considering COBRA Following a Disability Global Leader In Age Management Announces New Indiana Medical Center Collaborative Efforts Prove Effective for QHR Client Hospital Gritman Medical Center and Neighboring Pullman Regional Hospital DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal USPTO Issues Patent Embodying Methodologies for Abating a Broad Range of Allergens, Pathogens, Viruses, Bacteria, Odors and Volatile Organic Compounds.

(Date:12/1/2009)..., , MINNETONKA, Minn., Dec. 1 /PRNewswire/...ology solutions company specializing in clinical s...IGHTEN ®, its industry-leading EDC/eClinical ...nical Data Interchange Standards Consortium (CDISC...M) standard. This certification underscores MedNe...

(Date:12/1/2009)..., , CAMBRIDGE, Mass. and TOKYO, Dec. 1 /PR...al Co., Ltd. announced today the further extension...hrough 2011. This latest extension increases the ...otal committed funding to approximately $90 millio... January 2005 with the goal of discovering and dev...

(Date:12/1/2009)..., , CLEARWATER, Fla., Dec. 1 /PRNewswire/ ...provider of medical supplies, today announced that...ankruptcy Court for District of Delaware (the "Cou... the marketing and proposed sale of substantially ...d November 24, 2009, the Court approved bidding pr...

Breaking Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2 Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2 Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3 CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures 2 Evolution of a contraceptive for sea lamprey 8994 1 Evolution of a contraceptive for sea lamprey 8994 2 AAHSA Statement on House Ways and Means Committee Hearing 49988 1 AAHSA Statement on House Ways and Means Committee Hearing 49988 2 Allscripts to Announce Fiscal Fourth Quarter and Year End Results on July 20 2009 49984 1 Allscripts to Announce Fiscal Fourth Quarter and Year End Results on July 20 2009 49984 2 Allscripts to Announce Fiscal Fourth Quarter and Year End Results on July 20 2009 49984 3 Allscripts to Announce Fiscal Fourth Quarter and Year End Results on July 20 2009 49984 4

[0] MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification [0] Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration [0] CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures

...ecting Devastating Genetic Diseases -, PHILADELPH...ell connected to other areas, researchers successf...in -- after one injection of,gene therapy. If thes...earchers may have a potential method for gene ther...ital human neurological disorders, such as,Tay-Sac...

...eutics, Inc., a,privately-held biopharmaceutical c...ation of proprietary compounds to treat gastrointe...has completed the patient enrollment,of its Phase ...al,double-blind, placebo controlled study, FHAST1 ...to determine the efficacy and safety of oral,AST-1...

Other Medicine Technology:One Shot of Gene Therapy Spreads Through Brain in Animal Study 2 One Shot of Gene Therapy Spreads Through Brain in Animal Study 3 Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease 2 Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease 3

One Shot of Gene Therapy Spreads Through Brain in Animal Study Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease

...channel within a 12.1mm insertion tube. It featur...d image for improved reliability, an electronic be...5 and 5.0mhz transducer for deeper ultrasound imag...ical orientation and vascular evaluation during re...

...of diagnosis by using the Convex Scanning method. ...od flow by using the Color Flow Mapping and Color ...rated and the balloon fixation has improved. Those...curate techniques. The FG-36UX expands the possibi...

ACL 1000 Coagulation Analyzer

SYNCHRON CX®5 Delta

Medicine Products:

Linear Endoscope Ultrasound (EG-3630U)Linear Endoscope Ultrasound (FG-36Ux)ACL 1000 Coagulation Analyzer SYNCHRON CX®5 Delta

Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihyperten...( HAYWARD Calif. Nov. 1 /- Arete Th...),Health